Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection

Phase 1

Suspended

• Conditions: Brain Gliomas
• Interventions: Biological: Allogenic B7H3 CAR-γδT cell

• Registration Number: NCT06018363
• Lead Sponsor: Dushu Lake Hospital Affiliated to Soochow University

Brief Summary

This is a study on the clinical application of chimeric antigen receptor modified γδ T cells (CAR-γδ T cells) in relapsed and refractory B7H3 Positive malignant brain glioma.The main purpose of this study was to evaluate the safety and feasibility of CAR-γδ T cell infusion in patients with relapsed and refractory B7H3 Positive malignant brain glioma.

Detailed Description

γδT cells are known as "a great candidate for car-t cells". Although they only account for 2% - 5% of all T cells in our body, they are a natural killer.

Treatment on this study includes six B7H3 CAR-γδ Tcell infusions over an 12 week period. B7H3 CAR-γδ T cells will be locoregionally administered via a CNS reservoir catheter without lymphodepleting chemotherapy. The study will evaluate the safety, feasibility and maximum tolerated dose (MTD) of B7H3 CAR-γδ T cell using a 3+3 study design and an 4 week evaluation period. The total study duration will be 2 years.

Study Timeline

• Study Start: 2023-06-01
• Study First Submitted: 2023-08-25
• Study First Submitted QC: 2023-08-25
• Study First Posted: 2023-08-30
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-17
• Last Update Posted: 2024-10-21
• Primary Completion: 2025-12-31
• Study Completion: 2026-12-31

Recruitment & Eligibility

• Status: SUSPENDED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• 1)Age 18-70 years old (both ends included), both male and female;
• 2)At least one evaluable lesion with previous biopsy or pathohistologic confirmation of high-grade glioma (WHO grade IV), with imaging suggestive of continued progression or recurrence after comprehensive treatment;
• 3. Surgically resected pathological tissue capable of being used for immunohistochemical detection of target proteins and positive for B7H3 expression;
• 4. KPS ≥ 60 points;
• 5)Expected survival > 3 months;
• 6)Substantially normal bone marrow reserve function and normal liver and renal function (laboratory tests need to be fulfilled before receiving QH104 Cell Injection for the first time):White blood cell count (WBC) ≥ 3 x 109/L;Lymphocyte count (LY) ≥ 0.8 x 109/L;Hemoglobin (Hb) ≥ 90g/L;Platelet (PLT) ≥80×109/L;Albumin transaminase (ALT) & albumin transaminase (AST) <1.5×ULN;Serum creatinine (Cr) <1.5 x ULN;Total bilirubin < 1.5 x ULN;PT & PTT ≤ 1.25 x ULN.
• 7)No obvious hereditary diseases;
• 8)Normal cardiac function with cardiac ejection index >55%;
• 9)No bleeding and coagulation disorders;
• 10)Women of childbearing age (15-49 years old) must have had a pregnancy test with a negative result within 7 days prior to the start of treatment, and subjects are willing to use contraception during the clinical trial and for 3 months after the last cell infusion;
• 11. Sign the informed consent form.

Exclusion Criteria

• 1)Pregnant and lactating women;
• 2)Those with organ failure:Heart: Class III and IV;Liver: up to grade C of the Child-Turcotte Liver -Function Classification;Kidney: chronic kidney disease stage 4 or above; renal insufficiency stage III or above;Lungs: symptoms of severe respiratory failure with involvement of other organs;Brain: central nervous system abnormalities or impaired consciousness;
• 3)patients with combined second tumors;
• 4)patients with active hepatitis B or C virus, HIV infection, or other untreated active infection;
• 5)any severe, uncontrolled systemic autoimmune disease or any unstable systemic disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn's disease, and temporal arteritis;
• 6)Current systemic use of steroid cell (except for recent or current use of inhaled steroids) substances;
• 7. have a chronic disease requiring immunologic or hormonal therapy;
• 8. have an allergy to immunotherapy and related cells;
• 9. 10)Patients with a history of organ transplantation or who are awaiting organ transplantation;
• 10)Participation in other clinical trials within the previous 30 days;
• 11)Those who are not suitable for clinical trials for other reasons in the opinion of the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
ARM	Allogenic B7H3 CAR-γδT cell	Patients with refractory or relapsed B7H3 positive GBM

Primary Outcome Measures

Name	Time	Method
Phase 1:Incidence of Dose-Limiting Toxicities (DLTs)	First infusion date of B7H3 CAR-γδT cells up to 28 days	DLT was defined as B7H3 CAR-γδT cells-related events with onset within first 28 days following infusion: The development of Grade (G) III-IV acute GVHD according to the Mount Sinai Acute GVHD International Consortium criteria; The development of G3 or higher grade CRS lasting \> 2 weeks; Any B7H3 CAR-γδT cells-related AE requiring intubation; All G4 non-hematologic toxicities. Symptoms of GVHD include but are not limited to skin rash, enterocolitis with diarrhea, liver dysfunction with jaundice, fever, weight loss, etc.
Phase 1: Incidence of Adverse Events (AEs)	12 months	AE is defined as any adverse medical event from the date of the cell infusion to 12 months after B7H3 CAR-γδT cells infusion. Among them, cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS) were graded according to American Society for Transplantation and Cellular Therapy (ASTCT) criteria, graft-versus-host disease (GVHD) according to criteria defined by the Mount Sinai Acute GVHD International Consortium. Other AEs were graded according to common terminology criteria for adverse events (CTCAE) v5.0.
Phase 1:Maximum tolerated dose (MTD)	First infusion date of B7H3 CAR-γδT cells up to 28 days	MTD is defined as the highest dose level of less than or equal to 2 DLT among the 6 subjects finally determined.
Phase 1: Recommended phase 2 dose (RP2D)	First infusion date of B7H3 CAR-γδT cells up to 28 days	The recommended dose for phase 2 was determined through phase 1 study.
Phase 2: Best objective Response Rate	12 months	The incidence of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or unevaluable (UE) as the best response to treatment assessed by investigators and based on the RANO assessment criterion.

Secondary Outcome Measures

Name	Time	Method
Phase 2: Progression Free Survival (PFS)	12 months	PFS is defined as the time from the B7H3 CAR-γδT cells infusion date to the date of disease progression assessed by investigators and based on the RANO assessment criterion, or death any cause. Participants not meeting the criteria for progression by the analysis data cutoff date were censored at their last evaluable disease assessment date.
Pharmacokinetics: Number and copy number of B7H3 CAR-γδT cells (phase 1 and phase 2)	First infusion date of B7H3 CAR-γδT cells up to 28 days	Number and copy number of B7H3 CAR-γδT cells were assessed by number in cerebrospinal fluid(CSF). CSF samples were collected before and after cell infusion to detect the number and copy number of B7H3 CAR-γδT cells, and to evaluate the pharmacokinetics of B7H3 CAR-γδT.
Phase 2: Overall Survival (OS)	12 months	OS is defined as the time from B7H3 CAR-γδT cells infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at their last contact date.
Pharmacodynamics: Peak level of cytokines in CSF (phase 1 and phase 2)	First infusion date of B7H3 CAR-γδT cells up to 28 days	The cytokines mainly include interleukin-1 (IL-1 ), IL-6, IL-8, IL-10, interferon-γ (IFN-γ). Peak was defined as the maximum post-baseline level of the cytokine.

Trial Locations

Locations (1)

Dushu Lake Hospital Affiliated to Soochow University; 🇨🇳 Suzhou, Jiangsu, China